by Alexander Röth, Andreas Hüttmann, Russell P

Slides:

Advertisements

Similar presentations

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

Advertisements

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Next-generation leukemia immunotherapy

How I treat autoimmune hemolytic anemias in adults

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients by Guillaume Dumas, Anoosha Habibi, Thierry Onimus,

Tax fingerprint in adult T-cell leukemia

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib by Jorge.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival by Monika Führer, Udo Rampf, Irith Baumann, Andreas.

by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff

Protease inhibitors potentiate chemotherapy-induced neutropenia

Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development.

by Sabah Sallah, and Jim Y. Wan

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH Sandra Habbig, MD, Carsten Bergmann, MD,

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Anergy: the CLL cell limbo

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

by Anita Hill, Peter Hillmen, Stephen J

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Chronic graft-versus-host disease

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies by Alexander Röth, Scott T. Rottinghaus, Anita.

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.

by Achille Iolascon, Hermann Heimpel, Anders Wahlin, and Hannah Tamary

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

by Geling Li, Emily Waite, and Julie Wolfson

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

by Wendy Lim, Sara K. Vesely, and James N. George

Overcoming “aspirin resistance” in MPN

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

How I treat paroxysmal nocturnal hemoglobinuria

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Cold agglutinin disease

Presentation transcript:

Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease by Alexander Röth, Andreas Hüttmann, Russell P. Rother, Ulrich Dührsen, and Thomas Philipp Blood Volume 113(16):3885-3886 April 16, 2009 ©2009 by American Society of Hematology

Effect of eculizumab in a patient with cold agglutinin disease. Effect of eculizumab in a patient with cold agglutinin disease. Levels of hemolysis (as measured by LDH, ○) and anemia (hemoglobin, ▲) were documented in the year before and after initiation of eculizumab treatment. Transfusion episodes (↑) are also shown. Alexander Röth et al. Blood 2009;113:3885-3886 ©2009 by American Society of Hematology